Matthew Martinez, MD

Articles by Matthew Martinez, MD

Mavacamten Safety and Real-World Data Emerging at ACC.26, With Matthew Martinez, MD

April 1st 2026

Martinez discusses the bigger picture of mavacamten, highlighting its safety and efficacy as well as recent real-world trial data in patients with HCM.

Implementing Cardiac Myosin Inhibitors in oHCM: Workflow and Team-Based Care

ByMatthew Martinez, MD,Mariko Harper, MD

March 17th 2026

Martinez and Harper outline practical workflows for initiating and titrating cardiac myosin inhibitors, emphasizing multidisciplinary team structure, telemedicine, and logistics around REMS and imaging.

Comprehensive oHCM Follow-up: Hub-and-Spoke Care and 4-Pillar Framework

ByMatthew Martinez, MD,Mariko Harper, MD

March 17th 2026

Martinez and Harper describe a hub-and-spoke model for HCM care, follow-up cadence, and a structured “4-pillar” framework for longitudinal management, including imaging, biomarkers, and family-based risk strategies.

Long-term Safety, REMS Data, and Echo Monitoring for oHCM Therapies

ByMatthew Martinez, MD,Mariko Harper, MD

March 17th 2026

Martinez and Harper review real-world REMS data on cardiac myosin inhibitors, refine approaches to safety monitoring, and question how frequently echocardiography is truly needed in stable oHCM patients.

Choosing Between Septal Reduction and Myosin Inhibitors in oHCM Patients

ByMatthew Martinez, MD,Mariko Harper, MD

March 16th 2026

Martinez and Harper discuss the limits of current therapies, the role of septal reduction procedures versus cardiac myosin inhibitors, and the complexities of managing younger and childbearing-age patients with oHCM.

Understanding Gradient Reduction Therapy and Cardiac Myosin Inhibitors in oHCM Care

ByMatthew Martinez, MD,Mariko Harper, MD

March 9th 2026

Experts explore the concept of “gradient reduction therapy,” the remodeling effects of cardiac myosin inhibitors, and the evolving role of traditional agents in oHCM.

Modern oHCM Management: Earlier Diagnosis and Cardiac Myosin Inhibitors

ByMatthew Martinez, MD,Mariko Harper, MD

March 2nd 2026

Experts introduce the contemporary treatment paradigm for oHCM, emphasizing earlier diagnosis, cardiac myosin inhibitor use, and objective assessment of “asymptomatic” patients.